EUCTR2021-002218-15-SE进行中（未招募）1 期
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors - An open-label, multicenter, randomized controlled trial comparing safety and efficacy of personalized vs non-personalized radionuclide therapy with 177Lu-DOTATOC - START-NET
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Region Skåne
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject has given written informed consent to participate in the study.
- •2. Age =18 years
- •3. ECOG performance status 0-1
- •4. Life expectancy > 3 months.
- •5. Presence of histologically confirmed, advanced, well-differentiated, inoperable NETof any primary tumor origin (except pheochromocytoma and paraganglioma) and any grade, with a maximum Ki67 of 50%
- •6. SSTR-expression (mean SUV) in tumor lesions = 2x mean SUV in normal liver on 68Ga-DOTA-PET performed = 3 months prior to randomization. Due to partial volume effects, tumor lesions smaller than 1 cm on CT or MRI should not be used to evaluate this eligibility criterium.
- •7. Radiologically progressive disease within the last 1-24 months according to common clinical criteria and confirmed by the institutional multidisciplinary conference for the treatment of NETs. The CT/MRI that shows tumor progression compared to screening/baseline must have been performed 1-24 months earlier.
- •8. All previous anti-tumor treatment except SSA must be terminated at least 4 weeks before start of treatment within the trial
- •9. Measurable disease according to RECIST v 1.1
- •10. Given the available, approved anti-tumor treatments and the specific characteristics of the patient and the tumor, the investigator judges PRRT to be the treatment of choice
- •11. GFR > 50 ml/min/1.73 m2 as determined by iohexol- or 51Cr-EDTA clearance, calculated according to a combination of LMR18 and CAPA formulas, or equally accurate method
- •12. Adequate hematological parameters as defined by: Hemoglobin > 90 g/L, platelets >100 x109/L, leukocytes > 3.0x109/L, neutrophils > 1.5 x109/L
- •13. Adequate hepatic function as defined by ASAT/ALAT < 3 x ULN, bilirubin < 2 x ULN, albumin > 25 g/L.
- •14. For women of child-bearing potential, highly effective contraception should be usedfrom the time of inclusion up to at least six months after the EOT visit. For details see appendix 5.
- •15. For male subjects living with a woman of child-bearing potential, adequate contraception should be used from the time of inclusion up to at least six months after the EOT visit. Adequate male contraception methods are vasectomy, surgical or pharmacological castration, or the use of condom during heterosexual intercourse.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 220
排除标准
- •1. Pregnancy or lactation
- •2. Previous treatment with PRRT for NET
- •3. Concomitant systemic anti-tumor therapy other than SSA
- •4. Participation or recent participation in a clinical study with an investigational product within 30 days of randomization.
- •5. Known hypersensitivity to edotreotide, octreotide, capecitabine or any of the excipients included in the preparations.
- •6. Contraindications for treatment with capecitabine:
- •a. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion.
- •b. New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure
- •c. Previous serious or unexpected reactions to fluoropyrimidine treatment
- •d. Known complete deficiency of dihydropyrimidine dehydrogenase (DPD)
- •e. Recent or concomitant treatment with brivudine
- •7. Discordance between CT/MRI/18F-FDG-PET and 68Ga-DOTA-PET, with evidence of tumor lesions without uptake on 68Ga-DOTA-PET
- •8. Liver-directed therapy of metastases (i.e. radioembolization, chemoembolization, radiofrequency ablation, surgery, etc) < 4 weeks prior to randomization.
- •9. Major surgery < 12 weeks prior to randomization.
- •10. Previous radiotherapy of any kind which has resulted in irradiation of both kidneys and/or > 50% of the red bone marrow.
- •11. Any other serious, uncontrolled medical or psychiatric condition including other advanced or metastatic malignant disease that, in the opinion of the investigator, precludes the patient from participation in the trial
- •12. Mental inability, reluctance or language difficulties that result in difficulty understanding the meaning of study participation
- •13. Inability or reluctance to adhere to the radiation safety instructions
研究者
相似试验
招募中
3 期
Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.Neuroendocrine TumorsNCT05387603Lund University Hospital300
进行中（未招募）
不适用
Targeted radionuclide therapy of neuroendocrine tumours using 177Lu-DOTATATE combined with induced local tumour up-regulation of somatostatin receptor expression for increased tumour dosage and tumour to background ratio - NET Therapy 177Lu-DOTATATEEUCTR2012-000266-38-DKDepartment of Nuclear Medicine, Odense University Hospital50
尚未招募
不适用
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal carcinomarectal cancer100179901001799110017998NL-OMON51912niversitair Medisch Centrum Utrecht45
招募中
不适用
Towards Response guided ADAptive Radiotherapy for organ preserving treatment of intermediate risk rectal cancer: a phase I dose finding trialrectal cancerNL-OMON22916MC Utrecht45
招募中
2 期
Integrative precision neuromodulation therapy for psychiatric disordersJPRN-jRCTs032210059Shinsuke Kito90